|
40 Companies |
|
36 Products |
|
36 Products |
|
38 Mechanisms of Action |
|
0 Trials |
|
262 News |
|
| «123456» |
- |||||||||| Xolair (omalizumab) / Roche, Novartis
New P3 trial: OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients (clinicaltrials.gov) - Jun 12, 2014
P3, N=320, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- ||| Berinert (C1 esterase inhibitor (human) IV) / CSL Behring
Trial completion: Patient Registry Study of Berinert® in Normal Clinical Practice (clinicaltrials.gov) - Jun 4, 2014
P=N/A, N=318, Completed, Sponsor: CSL Behring
Active, not recruiting --> Completed
- || Berinert (C1 esterase inhibitor (human) IV) / CSL Behring
Enrollment change: Patient Registry Study of Berinert® in Normal Clinical Practice (clinicaltrials.gov) - Jun 4, 2014
P=N/A, N=250, Active, not recruiting, Sponsor: CSL Behring
Active, not recruiting --> Completed N=100 --> 250
- Trial primary completion date: SOS AOH: A Call Center During HAE Attacks (SOS HAE) (clinicaltrials.gov) - May 29, 2014
P4, N=200, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
N=100 --> 250 Trial primary completion date: Mar 2015 --> Mar 2016
- Berinert (C1 esterase inhibitor (human) IV) / CSL Behring
P4 data, Trial primary completion date: Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert (clinicaltrials.gov) - May 25, 2014
P4, N=48, Active, not recruiting, Sponsor: CSL Behring
Trial primary completion date: Mar 2015 --> Mar 2016 Trial primary completion date: Sep 2016 --> Jan 2015
- | Berinert (C1 esterase inhibitor (human) IV) / CSL Behring
Enrollment closed, P4 data: Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert (clinicaltrials.gov) - May 14, 2014
P4, N=48, Active, not recruiting, Sponsor: CSL Behring
Trial primary completion date: Sep 2016 --> Jan 2015 Recruiting --> Active, not recruiting
- | quilizumab (MEMP1972A) / Roche
Enrollment closed: A Study of Quilizumab Versus Placebo in Patients With Refractory Chronic Spontaneous Urticaria (clinicaltrials.gov) - May 11, 2014
P2, N=32, Active, not recruiting, Sponsor: Genentech
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Firazyr (icatibant) / Takeda
Trial primary completion date: Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema (clinicaltrials.gov) - Apr 29, 2014
P0, N=32, Recruiting, Sponsor: Vanderbilt University
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2014 --> Jun 2015
- | avoralstat (BCX4161) / BioCryst
New P1 trial: A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161 (clinicaltrials.gov) - Apr 23, 2014
P1, N=18, Active, not recruiting, Sponsor: BioCryst Pharmaceuticals
- Xolair (omalizumab) / Roche, Novartis
Trial completion: Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients (clinicaltrials.gov) - Apr 13, 2014
P2/3, N=30, Completed, Sponsor: University Hospital Inselspital, Berne
Trial primary completion date: Dec 2014 --> Jun 2015 Recruiting --> Completed
- Orencia (abatacept) / BMS
Enrollment closed: Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis (clinicaltrials.gov) - Apr 7, 2014
P2, N=66, Active, not recruiting, Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting --> Completed Recruiting --> Active, not recruiting
- | prednisone delayed-release tablet / Generic mfg.
Trial termination: A Study Assessing the Efficacy and Safety of Lodotra (clinicaltrials.gov) - Mar 31, 2014
P3, N=62, Terminated, Sponsor: Mundipharma Research Limited
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated
- | prednisone delayed-release tablet / Generic mfg.
Enrollment change: A Study Assessing the Efficacy and Safety of Lodotra (clinicaltrials.gov) - Mar 31, 2014
P3, N=62, Terminated, Sponsor: Mundipharma Research Limited
Active, not recruiting --> Terminated N=471 --> 62
- avoralstat (BCX4161) / BioCryst
Enrollment closed: OPuS-1: Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE (clinicaltrials.gov) - Mar 18, 2014
P2, N=25, Active, not recruiting, Sponsor: BioCryst Pharmaceuticals
N=471 --> 62 Recruiting --> Active, not recruiting
- Trial completion: C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema (clinicaltrials.gov) - Feb 22, 2014
P2/3, N=6, Completed, Sponsor: Sanquin
Recruiting --> Active, not recruiting Not yet recruiting --> Completed
- || Trial completion: C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema (clinicaltrials.gov) - Feb 22, 2014
P3, N=15, Completed, Sponsor: Sanquin
Not yet recruiting --> Completed Not yet recruiting --> Completed
- | Trial completion: Kinetics, Efficacy and Safety of C1-Esteraseremmer-N (clinicaltrials.gov) - Feb 22, 2014
P2, N=12, Completed, Sponsor: Sanquin
Not yet recruiting --> Completed Recruiting --> Completed
- | Xolair (omalizumab) / Roche, Novartis
Trial completion: Effect of Anti-IgE in Chronic Urticaria (clinicaltrials.gov) - Feb 22, 2014
P2, N=20, Completed, Sponsor: Johns Hopkins University
Recruiting --> Completed No longer recruiting --> Completed
- | lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
Trial completion: Lamivudine for Chronic Hepatitis B (clinicaltrials.gov) - Feb 19, 2014
P2, N=60, Completed, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
No longer recruiting --> Completed No longer recruiting --> Completed
- || Berinert (C1 esterase inhibitor (human) IV) / CSL Behring
Enrollment closed: Patient Registry Study of Berinert® in Normal Clinical Practice (clinicaltrials.gov) - Feb 18, 2014
P=N/A, N=250, Active, not recruiting, Sponsor: CSL Behring
No longer recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion: Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria (clinicaltrials.gov) - Feb 15, 2014
P4, N=150, Completed, Sponsor: Grupo de Alergolog
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Clinical: DTCU: Dietary Treatment for Chronic Urticaria (clinicaltrials.gov) - Jan 26, 2014
P=N/A, N=78, Recruiting, Sponsor: Hong Kong Sanatorium & Hospital
- | AZD1981 / AstraZeneca
Enrollment open: Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines (clinicaltrials.gov) - Jan 23, 2014
P2a, N=48, Recruiting, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Xolair (omalizumab) / Roche, Novartis
Enrollment open: CUN-OMAL-UCOL: Efficacy Study of Omalizumab in Cholinergic Urticaria (clinicaltrials.gov) - Jan 17, 2014
P2, N=24, Recruiting, Sponsor: Clinica Universidad de Navarra, Universidad de Navarra
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | AZD1981 / AstraZeneca
New P2a trial: Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines (clinicaltrials.gov) - Jan 7, 2014
P2a, N=48, Recruiting, Sponsor: Johns Hopkins University
- ||| Quzyttir (cetirizine injection) / TerSera Therap
New P3 trial: Pilot Phase III Clinical Trial of JDP-205 IV Injection for Treatment of Acute Urticaria (clinicaltrials.gov) - Dec 26, 2013
P3, N=36, Recruiting, Sponsor: JDP Therapeutics, Inc.
- Xolair (omalizumab) / Roche, Novartis
New P2 trial: CUN-OMAL-UCOL: Efficacy Study of Omalizumab in Cholinergic Urticaria (clinicaltrials.gov) - Dec 12, 2013
P2, N=24, Recruiting, Sponsor: Clinica Universidad de Navarra, Universidad de Navarra
- | quilizumab (MEMP1972A) / Roche
Enrollment open: A Study of Quilizumab Versus Placebo in Patients With Refractory Chronic Spontaneous Urticaria (clinicaltrials.gov) - Nov 24, 2013
P2, N=30, Recruiting, Sponsor: Genentech
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | quilizumab (MEMP1972A) / Roche
New P2 trial: A Study of Quilizumab Versus Placebo in Patients With Refractory Chronic Spontaneous Urticaria (clinicaltrials.gov) - Nov 18, 2013
P2, N=30, Recruiting, Sponsor: Genentech
- avoralstat (BCX4161) / BioCryst
New P2 trial: OPuS-1: Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE (clinicaltrials.gov) - Nov 13, 2013
P2, N=25, Active, not recruiting, Sponsor: BioCryst Pharmaceuticals
- Actemra IV (tocilizumab) / Roche, JW Pharma
Trial termination: Tocilizumab for the Treatment of Behcet's Syndrome (clinicaltrials.gov) - Nov 7, 2013
P=N/A, N=1, Terminated, Sponsor: New York University School of Medicine
Not yet recruiting --> Recruiting Recruiting --> Terminated; low enrollment
- Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment change: Tocilizumab for the Treatment of Behcet's Syndrome (clinicaltrials.gov) - Nov 7, 2013
P=N/A, N=1, Terminated, Sponsor: New York University School of Medicine
Recruiting --> Terminated; low enrollment N=40 --> 1
- Xolair (omalizumab) / Roche, Novartis
Enrollment change: Efficacy and Safety Study of Omalizumab (Xolair (clinicaltrials.gov) - Nov 4, 2013
P2, N=20, Active, not recruiting, Sponsor: Clinica Universidad de Navarra, Universidad de Navarra
N=40 --> 1 N=40 --> 20
- Xolair (omalizumab) / Roche, Novartis
Enrollment closed: Efficacy and Safety Study of Omalizumab (Xolair (clinicaltrials.gov) - Nov 4, 2013
P2, N=20, Active, not recruiting, Sponsor: Clinica Universidad de Navarra, Universidad de Navarra
N=40 --> 20 Recruiting --> Active, not recruiting
- gevokizumab (S 78989) / Novartis
Enrollment closed: Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum (clinicaltrials.gov) - Nov 3, 2013
P2, N=8, Active, not recruiting, Sponsor: XOMA (US) LLC
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Humira (adalimumab) / Eisai, AbbVie
Clinical: Special Investigation in Patients With Intestinal Behcet's Disease (All Case Investigation) (clinicaltrials.gov) - Oct 9, 2013
P=N/A, N=250, Recruiting, Sponsor: AbbVie
- || New P3 trial: Methotrexate in the Treatment of Chronic Idiopathic Urticaria (clinicaltrials.gov) - Oct 8, 2013
P3, N=110, Recruiting, Sponsor: University Hospital, Tours
- | Enrollment open: Methotrexate in the Treatment of Chronic Idiopathic Urticaria (clinicaltrials.gov) - Oct 7, 2013
P3, N=110, Recruiting, Sponsor: University Hospital, Tours
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Xolair (omalizumab) / Roche, Novartis
Trial completion: Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment (clinicaltrials.gov) - Sep 23, 2013
P2, N=38, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Completed
- Trial completion: The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment (clinicaltrials.gov) - Sep 17, 2013
P=N/A, N=42, Completed, Sponsor: University of Nebraska
Recruiting --> Completed Recruiting --> Completed
- | New P4 trial: Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria (clinicaltrials.gov) - Sep 10, 2013
P4, N=150, Completed, Sponsor: Grupo de Alergolog
- | Humira (adalimumab) / AbbVie
Trial initiation date: Efficacy of Humira in Behcet Patients With Arthritis (clinicaltrials.gov) - Aug 19, 2013
P3, N=15, Recruiting, Sponsor: Rambam Health Care Campus
Recruiting --> Completed Initiation date: Sep 2012 --> Jul 2013
- | Humira (adalimumab) / AbbVie
Enrollment open: Efficacy of Humira in Behcet Patients With Arthritis (clinicaltrials.gov) - Aug 19, 2013
P3, N=15, Recruiting, Sponsor: Rambam Health Care Campus
Initiation date: Sep 2012 --> Jul 2013 Not yet recruiting --> Recruiting
- ||||||| Xolair (omalizumab) / Roche, Novartis
Trial completion: A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment (clinicaltrials.gov) - Aug 12, 2013
P3, N=319, Completed, Sponsor: Genentech
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Enrollment closed: Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions (clinicaltrials.gov) - Aug 5, 2013
P3, N=15, Active, not recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Clairyg (intravenous normal human immunoglobulin) / LFB SA
Trial completion: IGUS: Intravenous Immunoglobulins in Severe and Refractory Solar Urticaria (clinicaltrials.gov) - Jul 28, 2013
P2, N=10, Completed, Sponsor: Centre Hospitalier Universitaire de Besancon
Recruiting --> Active, not recruiting Recruiting --> Completed
- Actemra IV (tocilizumab) / Roche, JW Pharma
New P2 trial: HORTOCI: Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study. (clinicaltrials.gov) - Jul 25, 2013
P2, N=20, Not yet recruiting, Sponsor: Centre Hospitalier Universitaire Dijon
- || Humira (adalimumab) / Eisai, AbbVie
Trial completion: A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease (clinicaltrials.gov) - Jul 24, 2013
P3, N=20, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Completed Active, not recruiting --> Completed
- | hydroxyzine hydrochloride / Generic mfg., levocetirizine / Generic mfg.
Enrollment change: LevoHydroxy: Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses (clinicaltrials.gov) - Jul 14, 2013
P4, N=24, Completed, Sponsor: Association Asthma, Bulgaria
Active, not recruiting --> Completed N=40 --> 24
- | hydroxyzine hydrochloride / Generic mfg., levocetirizine / Generic mfg.
Trial completion: LevoHydroxy: Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses (clinicaltrials.gov) - Jul 14, 2013
P4, N=24, Completed, Sponsor: Association Asthma, Bulgaria
N=40 --> 24 Recruiting --> Completed